Safety, Efficacy, and Effectiveness of Maternal Vaccination against Respiratory Infections in Young Infants

Abstract

Lower respiratory tract infection (LRTI) is a major cause of neonatal morbidity and mortality worldwide. Maternal vaccination is an effective strategy in protecting young infants from LRTI, particularly in the first few months after birth when infant is most vulnerable, and most primary childhood vaccinations have not been administered. Additionally, maternal vaccination protects the mother from illness during pregnancy and the postnatal period, and the developing fetus from adverse outcomes such as stillbirth and prematurity. In this paper, we review the safety, efficacy, and effectiveness of maternal vaccines against LRTIs, such as pertussis, influenza, coronavirus disease 2019, and respiratory syncytial virus.

Keywords

pregnancy - vaccination - safety - immunogenicity - respiratory pathogens

^* Joint senior author

Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2024

• References

• 1 Bender RG, Sirota SB, Swetschinski LR. et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis 2024; 24 (09) 974-1002
• 2 Vos T, Lim SS, Abbafati C. et al; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396 (10258): 1204-1222
• 3 Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myer L, Nicol MP. Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study. Lancet Respir Med 2016; 4 (06) 463-472
• 4 Jain S, Williams DJ, Arnold SR. et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372 (09) 835-845
• 5 O'Brien KL, Baggett HC, Brooks WA. et al; Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet 2019; 394 
10200
: 757-779
• 6 Meissner HC. Viral bronchiolitis in children. N Engl J Med 2016; 374 (01) 62-72
• 7 von Mollendorf C, Berger D, Gwee A. et al; ARI review group. Aetiology of childhood pneumonia in low- and middle-income countries in the era of vaccination: a systematic review. J Glob Health 2022; 12: 10009
• 8 Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 2014; 35 (12) 519-530
• 9 Crofts KF, Alexander-Miller MA. Challenges for the newborn immune response to respiratory virus infection and vaccination. Vaccines (Basel) 2020; 8 (04) 558
• 10 Sanchez-Schmitz G, Levy O. Development of newborn and infant vaccines. Sci Transl Med 2011; 3 (90) 90ps27
• 11 WHO recommendations for routine immunization - summary tables. Accessed March 31, 2024 at: https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization—summary-tables
• 12 CDC. Immunization Schedules for 18 & Younger. Centers for Disease Control and Prevention. Accessed March 31, 2024 at: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html
• 13 Omer SB. Maternal immunization. N Engl J Med 2017; 376 (13) 1256-1267
• 14 Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and pregnancy. Emerg Infect Dis 2006; 12 (11) 1638-1643
• 15 Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med 2014; 370 (23) 2211-2218
• 16 Nishiura H. Smallpox during pregnancy and maternal outcomes. Emerg Infect Dis 2006; 12 (07) 1119-1121
• 17 Emerson H. Panum on measles: observations made during the epidemic of measles on the Faroe Islands in the year 1846 (a translation from the Danish). Am J Public Health Nations Health 1940; 30 (10) 1245-1246
• 18 Nuzum JW, Pilot I, Stangl FH, Bonar BE. 1918 pandemic influenza and pneumonia in a large civil hospital. Ill Med J 1976; 150 (06) 612-616
• 19 Harris JW. Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. J Am Med Assoc 1919; 72 (14) 978-980
• 20 Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959; 78: 1172-1175
• 21 Allotey J, Stallings E, Bonet M. et al; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370: m3320
• 22 Alkema L, Chou D, Hogan D. et al; United Nations Maternal Mortality Estimation Inter-Agency Group collaborators and technical advisory group. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet 2016; 387 (10017): 462-474
• 23 Hug L, Alexander M, You D, Alkema L. UN Inter-agency Group for Child Mortality Estimation. National, regional, and global levels and trends in neonatal mortality between 1990 and 2017, with scenario-based projections to 2030: a systematic analysis. Lancet Glob Health 2019; 7 (06) e710-e720
• 24 Etti M, Calvert A, Galiza E. et al. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol 2022; 226 (04) 459-474
• 25 de Martino M. Dismantling the taboo against vaccines in pregnancy. Int J Mol Sci 2016; 17 (06) 894
• 26 Schofield FD, Tucker VM, Westbrook GR. Neonatal tetanus in New Guinea. Effect of active immunization in pregnancy. BMJ 1961; 2 (5255): 785-789
• 27 Macklin R. Enrolling pregnant women in biomedical research. Lancet 2010; 375 (9715): 632-633
• 28 Expanded Programme on Immunization (EPI). Progress towards the global elimination of neonatal tetanus, 1989-1993. Wkly Epidemiol Rec 1995; 70 (12) 81-85
• 29 Vaccines against influenza WHO position paper—November 2012. Releve Epidemiol Hebd 2012; 87 (47) 461-476
• 30 Safety of immunization during pregnancy: a review of the evidence: Global Advisory Committee on Vaccine Safety. Accessed April 1, 2024 at: https://www.who.int/publications-detail-redirect/WHO-HIS-2014.07
• 31 Swamy GK, Heine RP. Vaccinations for pregnant women. Obstet Gynecol 2015; 125 (01) 212-226
• 32 Dad N, Buhmaid S, Mulik V. Vaccination in pregnancy - the when, what and how?. Eur J Obstet Gynecol Reprod Biol 2021; 265: 1-6
• 33 Castillo E, Patey A, MacDonald N. Vaccination in pregnancy: challenges and evidence-based solutions. Best Pract Res Clin Obstet Gynaecol 2021; 76: 83-95
• 34 Laris-González A, Bernal-Serrano D, Jarde A, Kampmann B. Safety of administering live vaccines during pregnancy: a systematic review and meta-analysis of pregnancy outcomes. Vaccines (Basel) 2020; 8 (01) 124
• 35 Pregnancy Guidelines and Recommendations by Vaccine. CDC. April 9, 2024. Accessed May 19, 2024 at: https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html
• 36 Dangor Z, Benson N, Berkley JA. et al. Vaccine value profile for Klebsiella pneumoniae . Vaccine 2024; 42 (19S1): S125-S141
• 37 Madhi SA, Anderson AS, Absalon J. et al. Potential for maternally administered vaccine for infant group B Streptococcus. N Engl J Med 2023; 389 (03) 215-227
• 38 Quincer EM, Cranmer LM, Kamidani S. Prenatal maternal immunization for infant protection: a review of the vaccines recommended, infant immunity and future research directions. Pathogens 2024; 13 (03) 200
• 39 Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
• 40 Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7 (09) 715-725
• 41 Linder N, Ohel G. In utero vaccination. Clin Perinatol 1994; 21 (03) 663-674
• 42 van den Berg JP, Westerbeek EA, van der Klis FR, Berbers GA, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev 2011; 87 (02) 67-72
• 43 Wilcox CR, Holder B, Jones CE. Factors affecting the FcRn-mediated transplacental transfer of antibodies and implications for vaccination in pregnancy. Front Immunol 2017; 8: 1294
• 44 Saso A, Kampmann B. Maternal immunization: nature meets nurture. Front Microbiol 2020; 11: 1499
• 45 Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014; 5: 446
• 46 Fouda GG, Martinez DR, Swamy GK, Permar SR. The impact of IgG transplacental transfer on early life immunity. Immunohorizons 2018; 2 (01) 14-25
• 47 Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis 2017; 17 (09) 974-980
• 48 Kandeil W, van den Ende C, Bunge EM, Jenkins VA, Ceregido MA, Guignard A. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis. Expert Rev Vaccines 2020; 19 (07) 621-638
• 49 Pertussis vaccines: WHO position paper—August 2015. Accessed April 1, 2024 at: https://www.who.int/publications-detail-redirect/WHO-WER9035
• 50 Sedighi I, Karimi A, Amanati A. Old disease and new challenges: major obstacles of current strategies in the prevention of pertussis. Iran J Pediatr 2016; 26 (04) e5514
• 51 Muloiwa R, Kagina BM, Engel ME, Hussey GD. The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a systematic review and meta-analysis. BMC Med 2020; 18 (01) 233
• 52 Plotkin SA. The pertussis problem. Clin Infect Dis 2014; 58 (06) 830-833
• 53 Tan T, Dalby T, Forsyth K. et al. Pertussis across the globe: recent epidemiologic trends from 2000 to 2013. Pediatr Infect Dis J 2015; 34 (09) e222-e232
• 54 Esposito S, Principi N. Prevention of pertussis: an unresolved problem. Hum Vaccin Immunother 2018; 14 (10) 2452-2459
• 55 Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002; 35 (02) 162-167
• 56 Tessier E, Newport D, Tran A. et al. Pertussis immunisation strategies to optimise infant pertussis control: a narrative systematic review. Vaccine 2023; 41 (41) 5957-5964
• 57 Decker MD, Edwards KM, Steinhoff MC. et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96 (3 Pt 2): 557-566
• 58 Dewan KK, Linz B, DeRocco SE, Harvill ET. Acellular pertussis vaccine components: today and tomorrow. Vaccines (Basel) 2020; 8 (02) 217
• 59 Abu Raya B, Srugo I, Kessel A, Peterman M, Vaknin A, Bamberger E. The decline of pertussis-specific antibodies after tetanus, diphtheria, and acellular pertussis immunization in late pregnancy. J Infect Dis 2015; 212 (12) 1869-1873
• 60 Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190 (02) 335-340
• 61 Amirthalingam G, Andrews N, Campbell H. et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384 (9953): 1521-1528
• 62 Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ 2014; 349: g4219
• 63 Kharbanda EO, Vazquez-Benitez G, Lipkind HS. et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 2014; 312 (18) 1897-1904
• 64 Kharbanda EO, Vazquez-Benitez G, Lipkind HS. et al. Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine 2016; 34 (07) 968-973
• 65 Vygen-Bonnet S, Hellenbrand W, Garbe E. et al. Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review. BMC Infect Dis 2020; 20 (01) 136
• 66 Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16 (20) 1901-1906
• 67 Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis . Vaccine 1998; 16 (20) 1907-1916
• 68 Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis . Vaccine 2003; 21 (25-26): 3542-3549
• 69 Taranger J, Trollfors B, Lagergård T. et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181 (03) 1010-1013
• 70 Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990; 161 (03) 487-492
• 71 Havers FP, Skoff TH, Rench MA. et al. Maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination during pregnancy: impact on infant anti-pertussis antibody concentrations by maternal pertussis priming series. Clin Infect Dis 2023; 76 (03) e1087-e1093
• 72 Cohen P, Scadron SJ. The placental transmission of protective antibodies against whooping cough: by inoculation of the pregnant mother. J Am Med Assoc 1943; 121 (09) 656-662
• 73 Mackin DW, Walker SP. The historical aspects of vaccination in pregnancy. Best Pract Res Clin Obstet Gynaecol 2021; 76: 13-22
• 74 Burdin N, Handy LK, Plotkin SA. What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis vaccines. Cold Spring Harb Perspect Biol 2017; 9 (12) a029454
• 75 Schwartz KL, Kwong JC, Deeks SL. et al. Effectiveness of pertussis vaccination and duration of immunity. CMAJ 2016; 188 (16) E399-E406
• 76 Edwards KM. Maternal antibodies and infant immune responses to vaccines. Vaccine 2015; 33 (47) 6469-6472
• 77 Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21 (24) 3406-3412
• 78 Voysey M, Kelly DF, Fanshawe TR. et al. The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses : an individual participant meta-analysis. JAMA Pediatr 2017; 171 (07) 637-646
• 79 Abu-Raya B, Maertens K, Munoz FM. et al. The effect of tetanus-diphtheria-acellular-pertussis immunization during pregnancy on infant antibody responses: individual-participant data meta-analysis. Front Immunol 2021; 12: 689394
• 80 Katz MA, Gessner BD, Johnson J. et al. Incidence of influenza virus infection among pregnant women: a systematic review. BMC Pregnancy Childbirth 2017; 17 (01) 155
• 81 Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12 (01) 15-22
• 82 Mertz D, Lo CKF, Lytvyn L, Ortiz JR, Loeb M. Flurisk-Investigators. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis. BMC Infect Dis 2019; 19 (01) 683
• 83 Tempia S, Walaza S, Cohen AL. et al. Mortality associated with seasonal and pandemic influenza among pregnant and nonpregnant women of childbearing age in a high-HIV-prevalence setting-South Africa, 1999-2009. Clin Infect Dis 2015; 61 (07) 1063-1070
• 84 Wang R, Yan W, Du M, Tao L, Liu J. The effect of influenza virus infection on pregnancy outcomes: a systematic review and meta-analysis of cohort studies. Int J Infect Dis 2021; 105: 567-578
• 85 Fell DB, Savitz DA, Kramer MS. et al. Maternal influenza and birth outcomes: systematic review of comparative studies. BJOG 2017; 124 (01) 48-59
• 86 Fell DB, Johnson J, Mor Z. et al. Incidence of laboratory-confirmed influenza disease among infants under 6 months of age: a systematic review. BMJ Open 2017; 7 (09) e016526
• 87 Vaccines against influenza: WHO position paper—May 2022. Accessed June 2, 2024 at: https://www.who.int/publications-detail-redirect/who-wer9719
• 88 Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: past, present, and future. Rev Med Virol 2022; 32 (01) e2243
• 89 Burney LE. Influenza immunization: statement. Public Health Rep 1960; 75 (10) 944
• 90 Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46 (RR-9): 1-25
• 91 Giles ML, Krishnaswamy S, Macartney K, Cheng A. The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review. Hum Vaccin Immunother 2019; 15 (03) 687-699
• 92 Foo DYP, Sarna M, Pereira G, Moore HC, Fell DB, Regan AK. Early childhood health outcomes following in utero exposure to influenza vaccines: a systematic review. Pediatrics 2020; 146 (02) e20200375
• 93 Foo D, Sarna M, Pereira G, Moore HC, Regan AK. Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: a longitudinal, population-based linked cohort study. PLoS Med 2022; 19 (04) e1003963
• 94 Foo D, Sarna M, Pereira G, Moore HC, Regan AK. Association between maternal influenza vaccination and neurodevelopmental disorders in childhood: a longitudinal, population-based linked cohort study. Arch Dis Child 2023; 108 (08) 647-653
• 95 Zaman K, Roy E, Arifeen SE. et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359 (15) 1555-1564
• 96 Steinhoff MC, Katz J, Englund JA. et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis 2017; 17 (09) 981-989
• 97 Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70 (04) 767-777
• 98 Amin AB, Nunes MC, Tapia MD. et al; for BMGF Supported Maternal Influenza Immunization Trials Investigators Group. Immunogenicity of influenza vaccines administered to pregnant women in randomized clinical trials in Mali and South Africa. Vaccine 2020; 38 (41) 6478-6483
• 99 Madhi SA, Cutland CL, Kuwanda L. et al; Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371 (10) 918-931
• 100 Nakabembe E, Cooper J, Amaral K. et al. The safety and immunogenicity of vaccines administered to pregnant women living with HIV: a systematic review and meta-analysis. EClinicalMedicine 2024; 69: 102448
• 101 Tapia MD, Sow SO, Tamboura B. et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 2016; 16 (09) 1026-1035
• 102 Regan AK, Klerk Nd, Moore HC, Omer SB, Shellam G, Effler PV. Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: a retrospective cohort study. Vaccine 2016; 34 (32) 3649-3656
• 103 Thompson MG, Kwong JC, Regan AK. et al; PREVENT Workgroup. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. Clin Infect Dis 2019; 68 (09) 1444-1453
• 104 de Bruin O, Phijffer E, Ahmadizar F. et al. Are maternal vaccines effective and safe for mothers and infants? A systematic review and meta-analysis of randomised controlled trials. BMJ Glob Health 2023; 8 (10) e012376
• 105 Nunes MC, Cutland CL, Dighero B. et al; Matflu Team. Kinetics of hemagglutination-inhibiting antibodies following maternal influenza vaccination among mothers with and those without HIV infection and their infants. J Infect Dis 2015; 212 (12) 1976-1987
• 106 Omer SB, Clark DR, Madhi SA. et al; BMGF Supported Maternal Influenza Immunization Trials Investigators Group. Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. Lancet Respir Med 2020; 8 (06) 597-608
• 107 Omer SB, Clark DR, Aqil AR. et al; for BMGF Supported Maternal Influenza Immunization Trials Investigators Group. Maternal influenza immunization and prevention of severe clinical pneumonia in young infants: analysis of randomized controlled trials conducted in Nepal, Mali and South Africa. Pediatr Infect Dis J 2018; 37 (05) 436-440
• 108 Li Y, Wang X, Blau DM. et al; Respiratory Virus Global Epidemiology Network, RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399 (10340): 2047-2064
• 109 Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V. WHO Product Development for Vaccines Advisory Committee. Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. Vaccine 2019; 37 (50) 7315-7327
• 110 Abrams EM, Doyon-Plourde P, Davis P. et al. Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people. Can Commun Dis Rep 2024; 50 (1-2): 1-15
• 111 Kenmoe S, Chu HY, Dawood FS. et al; PROMISE Investigators. Burden of respiratory syncytial virus-associated acute respiratory infections during pregnancy. J Infect Dis 2024; 229 (Suppl. 01) S51-S60
• 112 Phijffer EW, de Bruin O, Ahmadizar F. et al. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev 2024; 5 (05) CD015134
• 113 Muňoz FM, Swamy GK, Hickman SP. et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis 2019; 220 (11) 1802-1815
• 114 Dieussaert I, Hyung Kim J, Luik S. et al. RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes. N Engl J Med 2024; 390 (11) 1009-1021
• 115 Kampmann B, Madhi SA, Munjal I. et al; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388 (16) 1451-1464
• 116 Fleming-Dutra KE, Jones JM, Roper LE. et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72 (41) 1115-1122
• 117 Mapindra MP, Mahindra MP, McNamara P, Semple MG, Clark H, Madsen J. Respiratory syncytial virus maternal vaccination in infants below 6 months of age: meta-analysis of safety, immunogenicity, and efficacy. Neonatology 2024; 121 (03) 271-282
• 118 Madhi SA, Polack FP, Piedra PA. et al; Prepare Study Group. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med 2020; 383 (05) 426-439
• 119 Hermida N, Ferguson M, Leroux-Roels I. et al. Safety and immunogenicity of respiratory syncytial virus prefusion maternal vaccine coadministered with diphtheria-tetanus-pertussis vaccine: a phase 2 study. J Infect Dis 2024; 230 (02) e353-e362
• 120 Peterson JT, Zareba AM, Fitz-Patrick D. et al. Safety and immunogenicity of a respiratory syncytial virus prefusion f vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine. J Infect Dis 2022; 225 (12) 2077-2086
• 121 Falsey AR, Walsh EE, Scott DA. et al. Phase 1/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis 2022; 225 (12) 2056-2066
• 122 Oakes MC, Kernberg AS, Carter EB. et al. Pregnancy as a risk factor for severe coronavirus disease 2019 using standardized clinical criteria. Am J Obstet Gynecol MFM 2021; 3 (03) 100319
• 123 Stock SJ, Moore E, Calvert C. et al. Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study. Lancet Respir Med 2022; 10 (12) 1129-1136
• 124 Celewicz A, Celewicz M, Michalczyk M. et al. Pregnancy as a risk factor of severe COVID-19. J Clin Med 2021; 10 (22) 5458
• 125 Phoswa WN, Khaliq OP. Is pregnancy a risk factor of COVID-19?. Eur J Obstet Gynecol Reprod Biol 2020; 252: 605-609
• 126 Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226 (01) 68-89.e3
• 127 Gurol-Urganci I, Jardine JE, Carroll F. et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol 2021; 225 (05) 522.e1-522.e11
• 128 Flaxman S, Whittaker C, Semenova E. et al. Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US. JAMA Netw Open 2023; 6 (01) e2253590
• 129 Ciapponi A, Berrueta M. , P K Parker E, et al. Safety of COVID-19 vaccines during pregnancy: a systematic review and meta-analysis. Vaccine 2023; 41 (25) 3688-3700
• 130 Baden LR, El Sahly HM, Essink B. et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384 (05) 403-416
• 131 Polack FP, Thomas SJ, Kitchin N. et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383 (27) 2603-2615
• 132 COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care. Accessed April 3, 2024 at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care
• 133 Dunkle LM, Kotloff KL, Gay CL. et al; 2019nCoV-301 Study Group. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med 2022; 386 (06) 531-543
• 134 El Sahly HM, Baden LR, Essink B. et al; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021; 385 (19) 1774-1785
• 135 Sadoff J, Gray G, Vandebosch A. et al; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021; 384 (23) 2187-2201
• 136 Shimabukuro TT, Kim SY, Myers TR. et al; CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med 2021; 384 (24) 2273-2282
• 137 Prasad S, Kalafat E, Blakeway H. et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun 2022; 13 (01) 2414
• 138 Moro PL, Olson CK, Clark E. et al. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021. Vaccine 2022; 40 (24) 3389-3394
• 139 COVID-19 medicines | European Medicines Agency. Accessed April 3, 2024 at: https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines
• 140 Head Zauche L, Wallace B, Smoots AN. et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. Res Sq 2021; rs.3.rs-798175
• 141 Yang YJ, Murphy EA, Singh S. et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 2022; 139 (03) 373-380
• 142 Rottenstreich A, Zarbiv G, Oiknine-Djian E. et al. Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study. Clin Microbiol Infect 2022; 28 (03) 419-425
• 143 Rottenstreich A, Zarbiv G, Oiknine-Djian E. et al. Kinetics of maternally derived anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in infants in relation to the timing of antenatal vaccination. Clin Infect Dis 2023; 76 (03) e274-e279
• 144 Prahl M, Golan Y, Cassidy AG. et al. Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy. Nat Commun 2022; 13 (01) 4422
• 145 Halasa NB, Olson SM, Staat MA. et al; Overcoming COVID-19 Investigators. Maternal vaccination and risk of hospitalization for COVID-19 among Infants. N Engl J Med 2022; 387 (02) 109-119
• 146 Cao L, Lou J, Chan SY. et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nat Med 2022; 28 (08) 1715-1722
• 147 Razai MS, Mansour R, Ravindran P. et al. Facilitators and barriers to vaccination uptake in pregnancy: a qualitative systematic review. PLoS One 2024; 19 (04) e0298407
• 148 Razzaghi H, Kahn KE, Black CL. et al. Influenza and Tdap vaccination coverage among pregnant women - United States, April 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (39) 1391-1397
• 149 Bishop K, McMorrow M, Meiring S. et al. An evaluation of an influenza vaccination campaign targeting pregnant women in 27 clinics in two provinces of South Africa, 2015 - 2018. BMC Health Serv Res 2021; 21 (01) 941
• 150 Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. COVID-19 vaccination hesitancy. BMJ 2021; 373 (1138): n1138
• 151 Costantino C, Mazzucco W, Bonaccorso N. et al. Educational interventions on pregnancy vaccinations during childbirth classes improves vaccine coverages among pregnant women in Palermo's Province. Vaccines (Basel) 2021; 9 (12) 1455
• 152 Razai MS, Mansour R, Goldsmith L. et al. Interventions to increase vaccination against COVID-19, influenza and pertussis during pregnancy: a systematic review and meta-analysis. J Travel Med 2023; 30 (08) taad138
• 153 Knudsen J, Perlman-Gabel M, Uccelli IG, Jeavons J, Chokshi DA. Combating misinformation as a core function of public health. NEJM Catal 2023; CAT.22.0198
• 154 Simas C, Larson HJ. Overcoming vaccine hesitancy in low-income and middle-income regions. Nat Rev Dis Primers 2021; 7 (01) 41
• 155 Davies B, Olivier J, Amponsah-Dacosta E. Health systems determinants of delivery and uptake of maternal vaccines in low- and middle-income countries: a qualitative systematic review. Vaccines (Basel) 2023; 11 (04) 869
• 156 Mbunge E, Sibiya MN. Mobile health interventions for improving maternal and child health outcomes in South Africa: a systematic review. Glob Health J 2024; 8 (03) 102-112
• 157 Norman G, Kletter M, Dumville J. Interventions to increase vaccination in vulnerable groups: rapid overview of reviews. BMC Public Health 2024; 24 (01) 1479
• 158 Roos N, Lambach P, Mantel C. et al; MIACSA expert advisory panel group. Maternal Immunization and Antenatal Care Situation Analysis (MIACSA) study protocol: a multiregional, cross-sectional analysis of maternal immunization delivery strategies to reduce maternal and neonatal morbidity and mortality. BMJ Open 2019; 9 (06) e024449
• 159 WHO recommendations on antenatal care for a positive pregnancy experience. Accessed June 2, 2024 at: https://www.who.int/publications-detail-redirect/9789241549912
• 160 Hausdorff WP, Madhi SA, Kang G, Kaboré L, Tufet Bayona M, Giersing BK. Facilitating the development of urgently required combination vaccines. Lancet Glob Health 2024; 12 (06) e1059-e1067
• 161 Liang JL, Tiwari T, Moro P. et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018; 67 (02) 1-44
• 162 Simionescu AA, Streinu-Cercel A, Popescu FD. et al. Comprehensive overview of vaccination during pregnancy in Europe. J Pers Med 2021; 11 (11) 1196
• 163 WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines: an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios. Accessed March 16, 2024 at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1
• 164 Abrysvo | European Medicines Agency. Accessed June 8, 2024 at: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo
• 165 Ayouni I, Amponsah-Dacosta E, Noll S, Kagina BM, Muloiwa R. Interventions to improve knowledge, attitudes, and uptake of recommended vaccines during pregnancy and postpartum: a scoping review. Vaccines (Basel) 2023; 11 (12) 1733
• 166 Álvarez Aldean J, Rivero Calle I, Rodríguez Fernández R. et al. Cost-effectiveness analysis of maternal immunization with RSVpreF vaccine for the prevention of respiratory syncytial virus among infants in Spain. Infect Dis Ther 2024; 13 (06) 1315-1331
• 167 Malhotra S, Cameron AI, Gotham D. et al. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. PLOS Glob Public Health 2024; 4 (07) e0003418
• 168 Nunes C, McKee M, Howard N. The role of global health partnerships in vaccine equity: a scoping review. PLOS Glob Public Health 2024; 4 (02) e0002834